160 related articles for article (PubMed ID: 29702806)
1. An Overview of the Orphan Medicines Market in Turkey.
Koçkaya G; Wertheimer AI; Kilic P; Tanyeri P; Mert Vural I; Akbulat A; Artiran G; Kerman S
Value Health Reg Issues; 2014 Sep; 4():47-52. PubMed ID: 29702806
[TBL] [Abstract][Full Text] [Related]
2. Analysis of patient access to orphan drugs in Turkey.
Koçkaya G; Atalay S; Oğuzhan G; Kurnaz M; Ökçün S; Sar Gedik Ç; Şaylan M; Şencan N
Orphanet J Rare Dis; 2021 Feb; 16(1):68. PubMed ID: 33549137
[TBL] [Abstract][Full Text] [Related]
3. Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries.
Gammie T; Lu CY; Babar ZU
PLoS One; 2015; 10(10):e0140002. PubMed ID: 26451948
[TBL] [Abstract][Full Text] [Related]
4. Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.
Blankart CR; Stargardt T; Schreyögg J
Pharmacoeconomics; 2011 Jan; 29(1):63-82. PubMed ID: 21073206
[TBL] [Abstract][Full Text] [Related]
5. Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
Orofino J; Soto J; Casado MA; Oyagüez I
Appl Health Econ Health Policy; 2010; 8(5):301-15. PubMed ID: 20804223
[TBL] [Abstract][Full Text] [Related]
6. [Orphan diseases and orphan medicines: a Belgian and European study].
Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
J Pharm Belg; 2009 Dec; (4):131-7. PubMed ID: 20183989
[TBL] [Abstract][Full Text] [Related]
7. Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment.
Malinowski KP; Kawalec P; Trabka W; Sowada C; Pilc A
Front Pharmacol; 2018; 9():1263. PubMed ID: 30483124
[No Abstract] [Full Text] [Related]
8. Impact of orphan drugs on Latvian budget.
Logviss K; Krievins D; Purvina S
Orphanet J Rare Dis; 2016 May; 11(1):59. PubMed ID: 27169704
[TBL] [Abstract][Full Text] [Related]
9. Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries.
Jakubowski S; Kawalec P; Holko P; Kowalska-Bobko I; Kamusheva M; Petrova G; Draganić P; Fuksa L; Männik A; Ispán F; Briedis V; Bianchi I; Paveliu MS; Tesar T
Front Pharmacol; 2024; 15():1369178. PubMed ID: 38523639
[No Abstract] [Full Text] [Related]
10. Access to medicines in Turkey: Evaluation of the process of medicines brought from abroad.
Atikeler EK; Leufkens HGMB; Goettsch W
Int J Technol Assess Health Care; 2020 Dec; 36(6):585-591. PubMed ID: 33231162
[TBL] [Abstract][Full Text] [Related]
11. Orphan Drug Prices and Epidemiology of Rare Diseases: A Cross-Sectional Study in Italy in the Years 2014-2019.
Villa F; Di Filippo A; Pierantozzi A; Genazzani A; Addis A; Trifirò G; Cangini A; Tafuri G; Settesoldi D; Trotta F
Front Med (Lausanne); 2022; 9():820757. PubMed ID: 35252257
[TBL] [Abstract][Full Text] [Related]
12. Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries.
Kamusheva M; Manova M; Savova AT; Petrova GI; Mitov K; Harsányi A; Kaló Z; Márky K; Kawalec P; Angelovska B; Lakić D; Tesar T; Draganic P; Geitona M; Hatzikou M; Paveliu MS; Männik A
Front Pharmacol; 2018; 9():795. PubMed ID: 30079023
[No Abstract] [Full Text] [Related]
13. Market uptake of orphan drugs--a European analysis.
Picavet E; Annemans L; Cleemput I; Cassiman D; Simoens S
J Clin Pharm Ther; 2012 Dec; 37(6):664-7. PubMed ID: 22731105
[TBL] [Abstract][Full Text] [Related]
14. Saving orphan drug legislations: misconceptions and clarifications.
Hyry HI; Cox TM; Roos JC
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):111-7. PubMed ID: 26768506
[TBL] [Abstract][Full Text] [Related]
15. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
16. Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis.
Chan AYL; Chan VKY; Olsson S; Fan M; Jit M; Gong M; Zhang S; Ge M; Pathadka S; Chung CCY; Chung BHY; Chui CSL; Chan EW; Wong GHY; Lum TY; Wong ICK; Ip P; Li X
Value Health; 2020 Dec; 23(12):1580-1591. PubMed ID: 33248513
[TBL] [Abstract][Full Text] [Related]
17. Availability and Access to Orphan Drugs for Rare Cancers in Bulgaria: Analysis of Delays and Public Expenditures.
Kostadinov K; Popova-Sotirova I; Marinova Y; Musurlieva N; Iskrov G; Stefanov R
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672571
[TBL] [Abstract][Full Text] [Related]
18. Determinants of orphan drugs prices in France: a regression analysis.
Korchagina D; Millier A; Vataire AL; Aballea S; Falissard B; Toumi M
Orphanet J Rare Dis; 2017 Apr; 12(1):75. PubMed ID: 28427466
[TBL] [Abstract][Full Text] [Related]
19. Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries.
Malinowski KP; Kawalec P; Trąbka W; Czech M; Petrova G; Manova M; Savova A; Draganić P; Vostalová L; Slabý J; Männik A; Márky K; Rugaja Z; Gulbinovic J; Tesar T; Paveliu MS
Front Pharmacol; 2019; 10():487. PubMed ID: 31139080
[TBL] [Abstract][Full Text] [Related]
20. Access to orphan drugs in Europe: current and future issues.
Michel M; Toumi M
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]